William Richard White - Dec 21, 2021 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Financial Officer
Signature
/s/ Jonathan Young, Attorney-in-fact
Stock symbol
AKRO
Transactions as of
Dec 21, 2021
Transactions value $
-$1,499
Form type
4
Date filed
12/23/2021, 08:03 PM
Previous filing
Dec 20, 2021
Next filing
Jan 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $701 +100 +3.05% $7.01* 3.38K Dec 21, 2021 Direct
transaction AKRO Common Stock Sale -$2.2K -100 -2.96% $22.00 3.28K Dec 21, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -100 -0.03% $0.00 324K Dec 21, 2021 Common Stock 100 $7.01 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold pursuant to a Rule 10b5-1 trading plan dated June 2, 2021 previously adopted by the Reporting Person.
F2 25% of this option vested on April 1, 2020, and the remaining 75% of this option shall vest in 36 equal monthly installments thereafter.